series-a
Stage
1
Investors
About
Poplar Therapeutics develops novel anti-immunoglobulin E (anti-IgE) therapies aimed at treating food allergies and other atopic diseases by targeting IgE.
Explore Poplar Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.